Cargando…

Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy

The burden of cancer is increasing, being widely recognized as one of the main reasons for deaths among humans. Despite the tremendous efforts that have been made worldwide to stem the progression and metastasis of cancer, morbidity and mortality in malignant tumors have been clearly rising and thre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Fengzhi, Liu, Jianhua, Zhang, Tianqi, Pang, Siwen, Yu, Haijia, Xu, Nannan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892763/
https://www.ncbi.nlm.nih.gov/pubmed/36741768
http://dx.doi.org/10.3389/fbioe.2023.1101673
_version_ 1784881385486417920
author Cui, Fengzhi
Liu, Jianhua
Zhang, Tianqi
Pang, Siwen
Yu, Haijia
Xu, Nannan
author_facet Cui, Fengzhi
Liu, Jianhua
Zhang, Tianqi
Pang, Siwen
Yu, Haijia
Xu, Nannan
author_sort Cui, Fengzhi
collection PubMed
description The burden of cancer is increasing, being widely recognized as one of the main reasons for deaths among humans. Despite the tremendous efforts that have been made worldwide to stem the progression and metastasis of cancer, morbidity and mortality in malignant tumors have been clearly rising and threatening human health. In recent years, nanomedicine has come to occupy an increasingly important position in precision oncotherapy, which improves the diagnosis, treatment, and long-term prognosis of cancer. In particular, LDNs with distinctive physicochemical capabilities have provided great potential for advanced biomedical applications, attributed to their large surface area, abundant surface binding sites, and good cellular permeation properties. In addition, LDNs can integrate CT/MR/US/PAI and PTT/PDT/CDT/NDDS into a multimodal theranostic nanoplatform, enabling targeted therapy and efficacy assessments for cancer. This review attempts to concisely summarize the classification and major properties of LDNs. Simultaneously, we particularly emphasize their applications in the imaging, diagnosis, and treatment of cancerous diseases.
format Online
Article
Text
id pubmed-9892763
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98927632023-02-03 Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy Cui, Fengzhi Liu, Jianhua Zhang, Tianqi Pang, Siwen Yu, Haijia Xu, Nannan Front Bioeng Biotechnol Bioengineering and Biotechnology The burden of cancer is increasing, being widely recognized as one of the main reasons for deaths among humans. Despite the tremendous efforts that have been made worldwide to stem the progression and metastasis of cancer, morbidity and mortality in malignant tumors have been clearly rising and threatening human health. In recent years, nanomedicine has come to occupy an increasingly important position in precision oncotherapy, which improves the diagnosis, treatment, and long-term prognosis of cancer. In particular, LDNs with distinctive physicochemical capabilities have provided great potential for advanced biomedical applications, attributed to their large surface area, abundant surface binding sites, and good cellular permeation properties. In addition, LDNs can integrate CT/MR/US/PAI and PTT/PDT/CDT/NDDS into a multimodal theranostic nanoplatform, enabling targeted therapy and efficacy assessments for cancer. This review attempts to concisely summarize the classification and major properties of LDNs. Simultaneously, we particularly emphasize their applications in the imaging, diagnosis, and treatment of cancerous diseases. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892763/ /pubmed/36741768 http://dx.doi.org/10.3389/fbioe.2023.1101673 Text en Copyright © 2023 Cui, Liu, Zhang, Pang, Yu and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Cui, Fengzhi
Liu, Jianhua
Zhang, Tianqi
Pang, Siwen
Yu, Haijia
Xu, Nannan
Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title_full Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title_fullStr Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title_full_unstemmed Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title_short Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
title_sort low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892763/
https://www.ncbi.nlm.nih.gov/pubmed/36741768
http://dx.doi.org/10.3389/fbioe.2023.1101673
work_keys_str_mv AT cuifengzhi lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy
AT liujianhua lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy
AT zhangtianqi lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy
AT pangsiwen lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy
AT yuhaijia lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy
AT xunannan lowdimensionalnanomaterialsasanemergingplatformforcancerdiagnosisandtherapy